Satellos Bioscience, Inc. (MSLE)
6.66
+0.31
(+4.88%)
USD |
NASDAQ |
Nov 06, 10:31
Satellos Bioscience Enterprise Value : 70.49M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 70.49M |
| November 04, 2026 | 72.99M |
| November 03, 2026 | 70.90M |
| November 02, 2026 | 71.53M |
| October 30, 2026 | 77.78M |
| October 29, 2026 | 80.18M |
| October 28, 2026 | 73.61M |
| October 27, 2026 | 81.53M |
| October 26, 2026 | 74.44M |
| October 23, 2026 | 71.94M |
| October 22, 2026 | 76.22M |
| October 21, 2026 | 77.78M |
| October 20, 2026 | 84.03M |
| October 19, 2026 | 72.36M |
| October 16, 2026 | 72.78M |
| October 15, 2026 | 80.70M |
| October 14, 2026 | 76.32M |
| October 13, 2026 | 84.86M |
| October 12, 2026 | 87.57M |
| October 09, 2026 | 94.24M |
| October 08, 2026 | 91.22M |
| October 07, 2026 | 97.16M |
| October 06, 2026 | 95.28M |
| October 05, 2026 | 105.91M |
| October 02, 2026 | 115.29M |
| Date | Value |
|---|---|
| October 01, 2026 | 115.29M |
| September 30, 2026 | 115.29M |
| September 29, 2026 | 117.37M |
| September 28, 2026 | 121.75M |
| September 25, 2026 | 119.46M |
| September 24, 2026 | 119.66M |
| September 23, 2026 | 113.41M |
| September 22, 2026 | 123.00M |
| September 21, 2026 | 129.46M |
| September 18, 2026 | 132.38M |
| September 17, 2026 | 139.88M |
| September 16, 2026 | 131.96M |
| September 15, 2026 | 133.21M |
| September 14, 2026 | 142.17M |
| September 11, 2026 | 141.34M |
| September 10, 2026 | 147.59M |
| September 09, 2026 | 146.96M |
| September 08, 2026 | 129.46M |
| September 04, 2026 | 125.08M |
| September 03, 2026 | 127.37M |
| September 02, 2026 | 126.75M |
| September 01, 2026 | 127.37M |
| August 31, 2026 | 132.79M |
| August 28, 2026 | 118.62M |
| August 27, 2026 | 138.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xenon Pharmaceuticals, Inc. | 2.721B |
| Psyence Biomedical Ltd. | -- |
| Aurinia Pharmaceuticals, Inc. | 1.744B |
| enGene Therapeutics, Inc. | -120.54M |
| Medicus Pharma Ltd. | 114.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.72M |
| Total Expenses (Quarterly) | 11.72M |
| EPS Diluted (Quarterly) | -0.5625 |
| Earnings Yield | -29.76% |
| Normalized Earnings Yield | -29.76 |